Sangui Biotech International, Inc. (SGBI)
Sangui Biotech International, Inc. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Hamburg, DE. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $41,980. On trailing twelve-month figures it carries a trailing P/E of -2.00, a net margin of -9.1%. Its beta of 0.71 implies it has historically moved less than the broad market.
Sangui Biotech International, Inc., through its subsidiary Sangui BioTech GmbH, specializes in creating artificial oxygen carriers derived from hemoglobin. These innovative products are utilized as blood supplements, blood volume replacements, and various related formulations. The company's oxygen carriers are vital for delivering oxygen to humans experiencing acute or chronic oxygen deprivation due to conditions like blocked arteries, anemia, or blood loss, as well as for managing chronic wounds. Their product line also includes nano-formulations designed for skin regeneration, enhancing moisture and elasticity. Furthermore, they provide Chitoskin wound pads to aid in healing and Hemospray, a medical-grade spray specifically formulated for treating persistent wounds. The wound spray products, marketed under the Granulox brand, are primarily distributed in Europe and Mexico, while their cosmetic items are available through an online store. Established in 1995, Sangui Biotech International, Inc. is based in Hamburg, Germany.
Sangui Biotech International, Inc. is most often compared with the following Healthcare names: